Alloantibody generation and effector function following sensitization to human leukocyte antigen

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Hickey, Michelle J ^a   Valenzuela, Nicole M ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allorecognition; Complement; Endothelium; Fc receptor; HLA antibody; Human leukocyte antigen; Non HLA antibody; Transplant

Indexed keywords

ALLOANTIBODY; ANAPHYLATOXIN; EPITOPE; HLA ANTIBODY; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN;

ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; COMPLEMENT SYSTEM; CROSS REACTION; GENETIC POLYMORPHISM; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; NONHUMAN; PREGNANCY; REVIEW; TRANSFUSION; TRANSPLANTATION; VENTRICULAR ASSIST DEVICE;

EID: 84961589943     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00030     Document Type: Review

References (154)

1. Steele DJ, Laufer TM, Smiley ST, Ando Y, Grusby MJ, Glimcher LH, et al. Two levels of help for B cell alloantibody production. J Exp Med (1996) 183(2):699-703. doi: 10.1084/jem.183.2.699.
2. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant (2008) 13(4):438-44. doi:10.1097/MOT.0b013e328309ee31.
3. Zhang JQ HM, Valenzuela NM, Zhang X, Lan JH, Cecka M, Reed EF. Histocompatibility and Immunogenetics for Solid Organ Transplantation. London: Springer Science+Business Media (2015).
4. IMGT/HLA. Available from: http://www.ebi.ac.uk/ipd/imgt/hla/stats.html.
5. Taylor AL, Negus SL, Negus M, Bolton EM, Bradley JA, Pettigrew GJ. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation (2007) 83(7):931-7. doi:10.1097/01.tp.0000257960.07783.e3.
6. Conlon TM, Saeb-Parsy K, Cole JL, Motallebzadeh R, Qureshi MS, Rehakova S, et al. Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol (2012) 188(6):2643-52. doi:10.4049/jimmunol.1102830.
7. Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation (1998) 97(13):1257-63. doi:10.1161/01.CIR.97.13.1257.
8. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol (1999) 162(1):352-8.
9. Hornick PI, Mason PD, Baker RJ, Hernandez-Fuentes M, Frasca L, Lombardi G, et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation (2000) 101(20):2405-10. doi:10.1161/01.CIR.101.20.2405.
10. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol (2001) 167(12):7199-206. doi:10.4049/jimmunol.167.12.7199.
11. Richters CD, van Gelderop E, du Pont JS, Hoekstra MJ, Kreis RW, Kamperdijk EW. Migration of dendritic cells to the draining lymph node after allogeneic or congeneic rat skin transplantation. Transplantation (1999) 67(6):828-32. doi:10.1097/00007890-199903270-00008.
12. Sandner SE, Salama AD, Houser SL, Palmer E, Turka LA, Sayegh MH. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant (2003) 3(10):1242-50. doi:10.1046/j.1600-6143.2003.00220.X.
13. Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T, et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation (1989) 48(4):608-13.
14. Schwarer AP, Jiang YZ, Deacock S, Brookes PA, Barrett AJ, Goldman JM, et al. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation (1994) 58(11):1198-203. doi:10.1097/00007890-199412270-00011.
15. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med (1982) 156(6):1835-41. doi:10.1084/jem.156.6.1835.
16. Braun MY, McCormack A, Webb G, Batchelor JR. Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation (1993) 55(1):177-82. doi:10.1097/00007890-199301000-00033.
17. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H Jr. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med (1994) 179(3):865-72. doi:10.1084/jem.179.3.865.
18. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol (1998) 161(11):5813-6.
19. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med (1997) 186(1):65-70. doi:10.1084/jem.186.1.65.
20. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474-8. doi:10.1038/30989.
21. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 393(6684):480-3. doi:10.1038/31002.
22. Smyth LA, Afzali B, Tsang J, Lombardi G, Lechler RI. Intercellular transfer of MHC and immunological molecules: molecular mechanisms and biological significance. Am J Transplant (2007) 7(6):1442-9. doi:10.1111/j.1600-6143.2007.01816.x.
23. Herrera OB, Golshayan D, Tibbott R, Salcido Ochoa F, James MJ, Marelli-Berg FM, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol (2004) 173(8):4828-37. doi:10.4049/jimmunol.173.8.4828.
24. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A novel pathway of antigen presentation by dendritic and endothelial cells: implications for allorecognition and infectious diseases. Transplantation (2006) 82(1 Suppl):S15-8. doi:10.1097/01.tp.0000231347.06149.ca.
25. Curry AJ, Pettigrew GJ, Negus MC, Easterfield AJ, Young JL, Bolton EM, et al. Dendritic cells internalise and re-present conformationally intact soluble MHC class I alloantigen for generation of alloantibody. Eur J Immunol (2007) 37(3):696-705. doi:10.1002/eji.200636543.
26. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, McHeyzer-Williams MG. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol (2009) 21(3):266-73. doi:10.1016/j.coi.2009.05.010.
27. Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN. SAP-controlled T-B cell interactions underlie germinal centre formation. Nature (2008) 455(7214):764-9. doi:10.1038/nature07186.
28. Cannons JL, Qi H, Lu KT, Dutta M, Gomez-Rodriguez J, Cheng J, et al. Optimal germinal center responses require a multistage T cell: B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity (2010) 32(2):253-65. doi:10.1016/j.immuni.2010.01.010.
29. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity (2007) 27(2):190-202. doi:10.1016/j.immuni.2007.07.009.
30. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science (2007) 315(5811):528-31. doi:10.1126/science.1136736.
31. Phan TG, Paus D, Chan TD, Turner ML, Nutt SL, Basten A, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med (2006) 203(11):2419-24. doi:10.1084/jem.20061254.
32. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature (2000) 407(6804):636-42. doi:10.1038/35036600.
33. Snanoudj R, Claas FH, Heidt S, Legendre C, Chatenoud L, Candon S. Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int (2015) 87(6):1230-40. doi:10.1038/ki.2014.390.
34. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant (2011) 11(9):1785-91. doi:10.1111/j.1600-6143.2011.03705.x.
35. Bestard O, Crespo E, Stein M, Lucia M, Roelen DL, de Vaal YJ, et al. Cross-validation of IFN-gamma Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant (2013) 13(7):1880-90. doi:10.1111/ajt.12285.
36. Hricik DE, Rodriguez V, Riley J, Bryan K, Tary-Lehmann M, Greenspan N, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant (2003) 3(7):878-84. doi:10.1034/j.1600-6143.2003.00132.x.
37. de Haan A, van den Berg AP, Hepkema BG, van Dijk E, Haagsma EB, The TH, et al. Donor-specific hyporeactivity after liver transplantation: prominent decreases in donor-specific cytotoxic T lymphocyte precursor frequencies independent of changes in helper T lymphocyte precursor frequencies or suppressor cell activity. Transplantation (1998) 66(4):516-22. doi:10.1097/00007890-199808270-00017.
38. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation (1997) 64(6):795-800. doi:10.1097/00007890-199712270-00033.
39. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest (1996) 98(5):1150-7. doi:10.1172/JCI118898.
40. Jackson KJ, Wang Y, Collins AM. Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels. Immunol Cell Biol (2014) 92(8):729-33. doi:10.1038/icb.2014.44.
41. van Zelm MC. B cells take their time: sequential IgG class switching over the course of an immune response? Immunol Cell Biol (2014) 92(8):645-6. doi:10.1038/icb.2014.48.
42. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.00520.
43. Devey ME, Bleasdale-Barr KM, Bird P, Amlot PL. Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology (1990) 70(2):168-74.
44. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol (2006) 67(11):847-62. doi:10.1016/j.humimm.2006.08.073.
45. Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, et al. Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol (2011) 85(3):1310-21. doi:10.1128/JVI.01966-10.
46. Mulder A, Eijsink C, Kester MG, Franke ME, Kardol MJ, Heemskerk MH, et al. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies. J Immunol (2005) 175(9):5950-7. doi:10.4049/jimmunol.175.9.5950.
47. Nakayama S, Kawaguchi G, Karaki S, Nagao T, Uchida H, Kashiwase K, et al. Effect of single amino acid substitution at residue 167 of HLA-B51 on binding of antibodies and recognition of T cells. Hum Immunol (1994) 39(3):211-9. doi:10.1016/0198-8859(94)90262-3.
48. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol (1994) 39(4):272-80. doi:10.1016/0198-8859(94)90270-4.
49. McKenzie LM, Pecon-Slattery J, Carrington M, O'Brien SJ. Taxonomic hierarchy of HLA class I allele sequences. Genes Immun (1999) 1(2):120-9. doi:10.1038/sj.gene.6363648.
50. Wade JA, Hurley CK, Takemoto SK, Thompson J, Davies SM, Fuller TC, et al. HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood (2007) 109(9):4064-70. doi:10.1182/blood-2006-06-032193.
51. Marrari M, Mostecki J, Mulder A, Claas F, Balazs I, Duquesnoy RJ. Human monoclonal antibody reactivity with human leukocyte antigen class I epitopes defined by pairs of mismatched eplets and self-eplets. Transplantation (2010) 90(12):1468-72. doi:10.1097/TP.0b013e3182007b74.
52. Lomago J, Jelenik L, Zern D, Howe J, Martell J, Zeevi A, et al. How did a patient who types for HLA-B*4403 develop antibodies that react with HLA-B*4402? Hum Immunol (2010) 71(2):176-8. doi:10.1016/j.humimm.2009.11.013.
53. Billen EV, Christiaans MH, Doxiadis II, Voorter CE, van den Berg-Loonen EM. HLA-DP antibodies before and after renal transplantation. Tissue Antigens (2010) 75(3):278-85. doi:10.1111/j.1399-0039.2009.01428.x.
54. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, Pando MJ, et al. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet (2013) 9(10):e1003938. doi:10.1371/journal.pgen.1003938.
55. Parham P, McLean J. Characterization, evolution, and molecular basis of a polymorphic antigenic determinant shared by HLA-A and B products. Hum Immunol (1980) 1(2):131-9. doi:10.1016/0198-8859(80)90100-7.
56. Tambur AR, Buckingham M, McDonald L, Luo X. Development of-donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. Clin Transpl (2006):399-404.
57. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation (2009) 88(4):447-52. doi:10.1097/TP.0b013e3181b04a5f.
58. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, et al. Class II HLA epitope matching-A strategy to minimize de novo-donor-specific antibody development and improve outcomes. Am J Transplant (2013) 13(12):3114-22. doi:10.1111/ajt.12478.
59. Laux G, Mansmann U, Deufel A, Opelz G, Mytilineos J. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation (2003) 75(9):1527-32. doi:10.1097/01.TP.0000061759.57702.8A.
60. Muro M, Gonzalez-Soriano MJ, Salgado G, Lopez R, Boix F, Lopez M, et al. Specific "intra-allele" and "intra-broad antigen" human leukocyte antigen alloantibodies in kidney graft transplantation. Hum Immunol (2010) 71(9):857-60. doi:10.1016/j.humimm.2010.05.018.
61. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation (2010) 90(10):1117-24. doi:10.1097/00007890-201007272-00536.
62. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation (2013) 95(4):635-40. doi:10.1097/TP.0b013e318277b30b.
63. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med (1995) 181(6):2085-95. doi:10.1084/jem.181.6.2085.
64. Apps R, Meng Z, Del Prete GQ, Lifson JD, Zhou M, Carrington M. Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. J Immunol (2015) 194(8):3594-600. doi:10.4049/jimmunol.1403234.
65. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol (2003) 14(5):1336-48. doi:10.1097/01.ASN.0000061778.08085.9F.
66. Dellgren C, Nehlin JO, Barington T. Cell surface expression level variation between two common Human Leukocyte Antigen alleles, HLA-A2 and HLA-B8, is dependent on the structure of the C terminal part of the alpha 2 and the alpha 3 domains. PLoS One (2015) 10(8):e0135385. doi:10.1371/journal.pone.0135385.
67. Ramsuran V, Kulkarni S, O'Huigin C, Yuki Y, Augusto DG, Gao X, et al. Epigenetic regulation of differential HLA-A allelic expression levels. Hum Mol Genet (2015) 24(15):4268-75. doi:10.1093/hmg/ddv158.
68. Giacomini P, Beretta A, Nicotra MR, Ciccarelli G, Martayan A, Cerboni C, et al. HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness. Tissue Antigens (1997) 50(6):555-66. doi:10.1111/j.1399-0039.1997.tb02913.x.
69. Sibilio L, Martayan A, Setini A, Lo Monaco E, Tremante E, Butler RH, et al. A single bottleneck in HLA-C assembly. J Biol Chem (2008) 283(3):1267-74. doi:10.1074/jbc.M708068200.
70. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 472(7344):495-8. doi:10.1038/nature09914.
71. Bryan CF, Luger AM, Smith JL, Warady BA, Wakefield M, Schadde E, et al. Sharing kidneys across donor-service area boundaries with sensitized candidates can be influenced by HLA C. Clin Transplant (2010) 24(1):56-61. doi:10.1111/j.1399-0012.2009.01167.x.
72. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 49(9):1825-35. doi:10.1111/j.1537-2995.2009.02206.x.
73. De Clippel D, Baeten M, Torfs A, Emonds MP, Feys HB, Compernolle V, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion (2014) 54(12):3036-42. doi:10.1111/trf.12727.
74. Hyun J, Park KD, Yoo Y, Lee B, Han BY, Song EY, et al. Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplant Proc (2012) 44(1):222-5. doi:10.1016/j.transproceed.2011.12.049.
75. Salvatierra O Jr, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg (1980) 192(4):543-52. doi:10.1097/00000658-198010000-00012.
76. Pfaff WW, Fennell RS, Howard RJ, Ireland JF, Scornik JC. Planned random donor blood transfusion in preparation for transplantation. Sensitization and graft survival. Transplantation (1984) 38(6):701-3. doi:10.1097/00007890-198412000-00030.
77. Josien R, Heslan M, Brouard S, Soulillou JP, Cuturi MC. Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion. Blood (1998) 92(12):4539-44.
78. Fuller TC, Delmonico FL, Cosimi B, Huggins CE, King M, Russell PS. Impact of blood transfusion on renal transplantation. Ann Surg (1978) 187(2):211-8. doi:10.1097/00000658-197802000-00020.
79. Scornik JC, Bromberg JS, Norman DJ, Bhanderi M, Gitlin M, Petersen J. An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol (2013) 14:217. doi:10.1186/1471-2369-14-217.
80. Regan L, Braude PR, Hill DP. A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum Reprod (1991) 6(2):294-8.
81. Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant (2011) 11(10):2132-43. doi:10.1111/j.1600-6143.2011.03640.x.
82. Masson E, Vidal C, Deschamps M, Bongain S, Thevenin C, Dupont I, et al. Incidence and risk factors of anti-HLA immunization after pregnancy. Hum Immunol (2013) 74(8):946-51. doi:10.1016/j.humimm.2013.04.025.
83. Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation (2011) 92(8):900-6. doi:10.1097/TP.0b013e31822dc38d.
84. Higgins R, Lowe D, Daga S, Hathaway M, Williams C, Lam FT, et al. Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Hum Immunol (2015) 76(8):546-52. doi:10.1016/j.humimm.2015.01.012.
85. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 95(3):410-7. doi:10.1097/TP.0b013e31827d62e3.
86. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 13(6):1541-8. doi:10.1111/ajt.12212.
87. Smith JD, Banner NR, Hamour M, Ozawa M, Goh A, Robinson D, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant (2011) 11(2):312-9. doi:10.1111/j.1600-6143.2010.03383.x.
88. Wiebe C, Gibson W, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 12(5):1157-67. doi:10.1111/j.1600-6143.2012.04013.x.
89. Billen EV, Christiaans MH, Lee J, van den Berg-Loonen EM. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Transplantation (2009) 87(4):563-9. doi:10.1097/TP.0b013e3181949e37.
90. Cecka JM, Terasaki PI. Repeating HLA antigen mismatches in renal retransplants-a second class mistake? Transplantation (1994) 57(4):515-9. doi:10.1097/00007890-199402000-00007.
91. Doxiadis II, de Lange P, D'Amaro J, de Meester J, Schreuder GM, Claas FH. Repeated HLA mismatches in cadaveric renal transplantation: is it safe to transplant? Transplant Proc (1997) 29(1-2):1408-9. doi:10.1016/S0041-1345(96)00612-4.
92. Fuller A, Profaizer T, Roberts L, Fuller TC. Repeat donor HLA-DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA-DR alloantibodies? Transplantation (1999) 68(4):589-91. doi:10.1097/00007890-199907270-00002.
93. Farney AC, Matas AJ, Noreen HJ, Reinsmoen N, Segall M, Schmidt WJ, et al. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? Clin Transplant (1996) 10(2):147-56.
94. House AA, Chang PC, Luke PP, Leckie SH, Howson WT, Ball EJ, et al. Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: multivariable analysis of 259 kidney retransplants. Transplantation (2007) 84(6):722-8. doi:10.1097/01.tp.0000281398.41670.1f.
95. Coupel S, Giral-Classe M, Karam G, Morcet JF, Dantal J, Cantarovich D, et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int (2003) 64(2):674-80. doi:10.1046/j.1523-1755.2003.00104.x.
96. O'Connor MJ, Lind C, Tang X, Gossett J, Weber J, Monos D, et al. Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. J Heart Lung Transplant (2013) 32(4):390-7. doi:10.1016/j.healun.2012.12.009.
97. Kwon MH, Zhang JQ, Schaenman JM, Cadeiras M, Gjertson DW, Krystal CA, et al. Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient. J Thorac Cardiovasc Surg (2015) 149(4):1161-6. doi:10.1016/j.jtcvs.2015.01.003.
98. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation (2008) 86(8):1111-5. doi:10.1097/01.tp.0000331682.91699.7b.
99. Burrows SR, Silins SL, Khanna R, Burrows JM, Rischmueller M, McCluskey J, et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol (1997) 27(7):1726-36. doi:10.1002/eji.1830270126.
100. Amir AL, D'Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood (2010) 115(15):3146-57. doi:10.1182/blood-2009-07-234906.
101. Morice A, Charreau B, Neveu B, Brouard S, Soulillou JP, Bonneville M, et al. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. PLoS One (2010) 5(8):e12120. doi:10.1371/journal.pone.0012120.
102. D'Orsogna LJ, van der Meer-Prins EM, Zoet YM, Roelen DL, Doxiadis II, Claas FH. Detection of allo-HLA cross-reactivity by virus-specific memory T-cell clones using single HLA-transfected K562 cells. Methods Mol Biol (2012) 882:339-49. doi:10.1007/978-1-61779-842-9_19.
103. de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, et al. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retroviruses (1994) 10(2):157-62. doi:10.1089/aid.1994.10.157.
104. Alberu J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl Immunol (2007) 18(2):166-71. doi:10.1016/j.trim.2007.06.001.
105. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol (2010) 185(3):1935-48. doi:10.4049/jimmunol.1000424.
106. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clin Transpl (2008):199-214. doi:10.1016/j.humimm.2009.06.020.
107. Roberts T, Tumer G, Gebel HM, Bray RA. Solid-phase assays for the detection of alloantibody against human leukocyte antigens: panacea or Pandora? Int J Immunogenet (2014) 41(5):362-9. doi:10.1111/iji.12138.
108. Visentin J, Guidicelli G, Bachelet T, Jacquelinet C, Audry B, Nong T, et al. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation (2014) 98(7):738-44. doi:10.1097/TP.0000000000000315.
109. In JW, Rho EY, Shin S, Park KU, Song EY. False-positive reactions against HLA class II molecules detected in Luminex single-antigen bead assays. Ann Lab Med (2014) 34(5):408-10. doi:10.3343/alm.2014.34.5.408.
110. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation (2009) 88(2):226-30. doi:10.1097/TP.0b013e3181ac6198.
111. Otten HG, Verhaar MC, Borst HP, van Eck M, van Ginkel WG, Hene RJ, et al. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol (2013) 173(3):536-43. doi:10.1111/cei.12127.
112. Jackson AM, Sigdel TK, Delville M, Hsieh SC, Dai H, Bagnasco S, et al. Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol (2015) 26(5):1161-71. doi:10.1681/ASN.2013121277.
113. Sun Q, Cheng Z, Cheng D, Chen J, Ji S, Wen J, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int (2011) 79(6):655-62. doi:10.1038/ki.2010.437.
114. Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation (2011) 91(10):1153-8. doi:10.1097/TP.0b013e3182157d60.
115. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 280(14):735-9. doi:10.1056/NEJM196904032801401.
116. Suitters A, Rose M, Higgins A, Yacoub MH. MHC antigen expression in sequential biopsies from cardiac transplant patients-correlation with rejection. Clin Exp Immunol (1987) 69(3):575-83.
117. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol (1990) 162(2):165-71. doi:10.1002/path.1711620115.
118. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res (2005) 11(23):8304-11. doi:10.1158/1078-0432.CCR-04-2588.
119. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 21(8):1398-406. doi:10.1681/ASN.2009101065.
120. Loupy A, Jordan SC. Transplantation: donor-specific HLA antibodies and renal allograft failure. Nat Rev Nephrol (2013) 9(3):130-1. doi:10.1038/nrneph.2013.18.
121. Valenzuela NM, Reed EF. Antibodies to HLA molecules mimic agonistic stimulation to trigger vascular cell changes and induce allograft injury. Curr Transplant Rep (2015) 2(3):222-32. doi:10.1007/s40472-015-0065-6.
122. Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci Signal (2010) 3(149):ra85. doi:10.1126/scisignal.2001158.
123. Jin YP, Fishbein MC, Said JW, Jindra PT, Rajalingam R, Rozengurt E, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol (2004) 65(4):291-302. doi:10.1016/j.humimm.2004.07.014.
124. Le Bas-Bernardet S, Coupel S, Chauveau A, Soulillou JP, Charreau B. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation (2004) 78(12):1729-39. doi:10.1097/01.TP.0000147339.31581.99.
125. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol (2004) 34(8):2303-12. doi:10.1002/eji.200324843.
126. Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, et al. Phosphorylated S6 ribosomal protein: a novel biomarker of-antibody-mediated rejection in heart allografts. Am J Transplant (2006) 6(7):1560-71. doi:10.1111/j.1600-6143.2006.01355.x.
127. Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 180(4):2214-24. doi:10.4049/jimmunol.180.4.2357.
128. Li F, Wei J, Valenzuela NM, Lai C, Zhang Q, Gjertson D, et al. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of-antibody-mediated rejection in heart allografts. J Heart Lung Transplant (2015) 34(4):580-7. doi:10.1016/j.healun.2014.09.047.
129. Ziegler ME, Jin YP, Young SH, Rozengurt E, Reed EF. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol (2012) 303(8):C872-82. doi:10.1152/ajpcell.00199.2012.
130. Ziegler ME, Souda P, Jin YP, Whitelegge JP, Reed EF. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One (2012) 7(1):e29472. doi:10.1371/journal.pone.0029472.
131. Galvani S, Auge N, Calise D, Thiers JC, Canivet C, Kamar N, et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant (2009) 9(11):2607-14. doi:10.1111/j.1600-6143.2009.02804.x.
132. Galvani S, Trayssac M, Auge N, Thiers JC, Calise D, Krell HW, et al. A key role for matrix metalloproteinases and neutral sphingomyelinase-2 in transplant vasculopathy triggered by anti-HLA antibody. Circulation (2011) 124(24):2725-34. doi:10.1161/CIRCULATIONAHA.111.021790.
133. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 104(4):1301-6. doi:10.1073/pnas.0602035104.
134. Valenzuela NM, Hong L, Shen XD, Gao F, Young SH, Rozengurt E, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2013) 13(2):299-311. doi:10.1111/ajt.12016.
135. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol (2013) 190(12):6635-50. doi:10.4049/jimmunol.1201434.
136. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM III. Antibody and complement in transplant vasculopathy. Circ Res (2007) 100(2):191-203. doi:10.1161/01.RES.0000255032.33661.88.
137. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant (2003) 18(11):2232-9. doi:10.1093/ndt/gfg304.
138. Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant (2005) 5(11):2778-85. doi:10.1111/j.1600-6143.2005.01074.x.
139. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med (2009) 206(12):2779-93. doi:10.1084/jem.20091107.
140. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113(16):3716-25. doi:10.1182/blood-2008-09-179754.
141. Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol (2011) 350:105-25. doi:10.1007/82_2010_86.
142. Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, et al. Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum (1998) 41(7):1181-9. doi:10.1002/1529-0131(199807)41:7<1181::AID-ART6>3.0.CO;2-C.
143. Karassa FB, Trikalinos TA, Ioannidis JP. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed Pharmacother (2004) 58(5):286-91. doi:10.1016/j.biopha.2004.04.004.
144. Diamantopoulos PT, Kalotychou V, Polonyfi K, Sofotasiou M, Anastasopoulou A, Galanopoulos A, et al. Correlation of Fc-gamma RIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. Leuk Lymphoma (2013) 54(9):2030-4. doi:10.3109/10428194.2012.762512.
145. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 6:1. doi:10.1186/1756-8722-6-1.
146. Maiga B, Dolo A, Toure O, Dara V, Tapily A, Campino S, et al. Fc gamma receptor IIa-H131R polymorphism and malaria susceptibility in sympatric ethnic groups, Fulani and Dogon of Mali. Scand J Immunol (2014) 79(1):43-50. doi:10.1111/sji.12122.
147. Pawlik A, Florczak M, Bak L, Domanski L, Rozanski J, Dabrowska-Zamojcin E, et al. The Fc gamma RIIa polymorphism in patients with acute kidney graft rejection. Ann Transplant (2003) 8(4):24-6.
148. Yuan FF, Watson N, Sullivan JS, Biffin S, Moses J, Geczy AF, et al. Association of Fc gamma receptor IIA polymorphisms with acute renal-allograft rejection. Transplantation (2004) 78(5):766-9. doi:10.1097/01.TP.0000132560.77496.CB.
149. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2013) 32(12):1147-62. doi:10.1016/j.healun.2012.11.005.
150. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol (2012) 73(12):1213-7. doi:10.1016/j.humimm.2012.07.011.
151. Fedrigo M, Feltrin G, Poli F, Frigo AC, Benazzi E, Gambino A, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant (2013) 32(4):404-9. doi:10.1016/j.healun.2012.12.017.
152. Xu L, Collins J, Drachenberg C, Kukuruga D, Burke A. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin Transplant (2014) 28(5):554-60. doi:10.1111/ctr.12348.
153. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int (2003) 63(5):1888-93. doi:10.1046/j.1523-1755.2003.00921.x.
154. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int (2005) 68(4):1866-74. doi:10.1111/j.1523-1755.2005.00606.x.